IDH2 and central nervous system cancer: CDKN2A homozygous deletion has been well‐analyzed in many tumors, including glioma, and frequently reported as a poor prognostic marker in patients with IDH‐mutant diffuse astrocytic glioma.10, 11, 12, 13, 14, 15, 16, 17